President and Chief Executive Officer of Ohana Biosciences
Amber Salzman is the President and CEO of Ohana Biosciences. She previously served as the President and CEO at Adverum Biotechnologies, and was a Co-Founder of Annapurna Therapeutics SAS where she served as its President and CEO prior to its merger with Avalanche Biosciences to create Adverum Biotechnologies.
Prior to her role at Adverum Biotechnologies, Amber served as President and CEO of Cardiokine, Inc. until it was acquired by Cornerstone Therapeutics. Prior to that, she was a member of the GlaxoSmithKline (GSK) research and development executive team, where she was responsible for operations for medicine development across therapeutic areas, including planning and managing drug development projects and clinical trials with over 30,000 active patients around the world.
In addition to her roles in industry, Amber is the President of the Stop ALD Foundation, a medical research foundation dedicated to finding better therapies for people with adrenoleukodystrophy and advocating on behalf of patients with rare diseases. She was instrumental in establishing the first gene therapy human proof-of-concept for ALD, and in adding ALD to the national recommended list of diseases for which newborns should be screened.
Additionally, she serves on the Boards of Lankenau Institute of Medical Research and Drexel University Dornsife School of Public Health.
Amber Salzman received her bachelor’s degree from Temple University and holds a Ph.D. in Mathematics from Bryn Mawr College. Honors include being inducted into Temple University's League of Entrepreneurial Women Hall of Fame.